OTCMKTS:CALA

Calithera Biosciences (CALA) Stock Price, News & Analysis

Calithera Biosciences logo
$0.0001 0.00 (-66.67%)
As of 03:49 PM Eastern

About Calithera Biosciences Stock (OTCMKTS:CALA)

Advanced

Key Stats

Today's Range
$0.0001
▼
$0.0001
50-Day Range
N/A
52-Week Range
$0.0001
▼
$0.0010
Volume
3,350 shs
Average Volume
420 shs
Market Capitalization
$386.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Calithera Biosciences, Inc. was a clinical-stage biotechnology company focused on developing small-molecule therapies that target cancer metabolism. The company’s research centered on metabolic pathways that tumors use to support growth and survival, with the goal of improving outcomes for patients with cancer.

Its lead investigational product was telaglenastat (CB-839), an oral inhibitor of glutaminase, an enzyme involved in glutamine metabolism. Calithera evaluated telaglenastat in combination with other treatments for cancers including renal cell carcinoma, triple-negative breast cancer and hematologic malignancies. The company also developed CB-280, an investigational arginase inhibitor intended for potential use in solid tumors.

Founded in 2010 and based in South San Francisco, California, Calithera conducted clinical-development activities primarily in the United States, with research and collaborations involving international pharmaceutical companies. Susan Molineaux, a co-founder, served as the company’s president and chief executive officer for much of its operating history. Calithera later discontinued development activities and ceased operating as an active biotechnology company.

AI Generated. May Contain Errors.

Receive CALA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Calithera Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CALA Stock News Headlines

Calithera Biosciences (CALA) Set to Post Earnings on Tuesday
Calithera Biosciences Inc (CALA)
Your book is inside
Blane Markham and the Markham Trading Team are giving readers a limited window to download their options strategy guide, titled How To Turn $100 Options Into $1,000 Gains, before it moves behind a paywall. The guide walks through options trading concepts the team uses in its own research and education materials. Once the paywall goes up, free access ends for good.tc pixel
Christina Cala
CALA - Calithera Biosciences, Inc.
Cala Mariolu
See More Headlines

CALA Stock Analysis - Frequently Asked Questions

Calithera Biosciences' stock was trading at $0.0001 at the start of the year. Since then, CALA stock has increased by 0.0% and is now trading at $0.0001.

Calithera Biosciences, Inc. (OTCMKTS:CALA) posted its earnings results on Monday, November, 8th. The biotechnology company reported ($3.00) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($4.60) by $1.60. The biotechnology company had revenue of $6.75 million for the quarter.

Shares of Calithera Biosciences reverse split on the morning of Wednesday, June 15th 2022.The 1-20 reverse split was announced on Wednesday, June 15th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of CALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Calithera Biosciences investors own include Alibaba Group (BABA), NVIDIA (NVDA), Tesla (TSLA), Bank of America (BAC), Advanced Micro Devices (AMD), Corbus Pharmaceuticals (CRBP) and Dynavax Technologies (DVAX).

Company Calendar

Today
11/18/2026
Next Earnings (Estimated)
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:CALA
Previous Symbol
NASDAQ:CALA
CIK
1496671
Fax
N/A
Employees
60
Year Founded
2010

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
3,860,000
Free Float
N/A
Market Cap
$386.00
Optionable
Not Optionable
Beta
-1.06

Social Links

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

This page (OTCMKTS:CALA) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners